Viewing Study NCT00485407



Ignite Creation Date: 2024-05-05 @ 5:35 PM
Last Modification Date: 2024-10-26 @ 9:33 AM
Study NCT ID: NCT00485407
Status: COMPLETED
Last Update Posted: 2007-11-01
First Post: 2007-06-11

Brief Title: Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine
Sponsor: Eli Lilly and Company
Organization: Eli Lilly and Company

Study Overview

Official Title: Guiding Dose Increases In Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine Concentrations a Randomized Double-Blind Study
Status: COMPLETED
Status Verified Date: 2007-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this trial is to test the value of dose increases in patients with residual ADHD symptoms after treatment with the usual target dose of atomoxetine
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
B4Z-MC-LYCL None None None